Biodesix, Inc. (BDSX)
NASDAQ: BDSX · Real-Time Price · USD
14.17
-0.59 (-4.00%)
At close: May 15, 2026, 4:00 PM EDT
13.94
-0.23 (-1.62%)
After-hours: May 15, 2026, 6:27 PM EDT
Biodesix Revenue
Biodesix had revenue of $25.56M in the quarter ending March 31, 2026, with 42.30% growth. This brings the company's revenue in the last twelve months to $96.10M, up 29.05% year-over-year. In the year 2025, Biodesix had annual revenue of $88.50M with 24.08% growth.
Revenue (ttm)
$96.10M
Revenue Growth
+29.05%
P/S Ratio
1.49
Revenue / Employee
$287,713
Employees
334
Market Cap
143.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 88.50M | 17.18M | 24.08% |
| Dec 31, 2024 | 71.32M | 22.24M | 45.30% |
| Dec 31, 2023 | 49.09M | 10.88M | 28.46% |
| Dec 31, 2022 | 38.21M | -16.29M | -29.89% |
| Dec 31, 2021 | 54.51M | 8.95M | 19.64% |
| Dec 31, 2020 | 45.56M | 21.01M | 85.55% |
| Dec 31, 2019 | 24.55M | 4.12M | 20.16% |
| Dec 31, 2018 | 20.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 829.00M |
| Castle Biosciences | 339.92M |
| Fulgent Genetics | 320.35M |
| MDxHealth | 110.97M |
| FONAR | 105.34M |
| Prenetics Global | 92.39M |
| Burning Rock Biotech | 77.14M |
| Exagen | 68.38M |
BDSX News
- 5 days ago - Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy - GlobeNewsWire
- 11 days ago - Biodesix price target raised to $22 from $20 at Canaccord - TheFly
- 12 days ago - Biodesix reports Q1 EPS (81c) vs. ($1.52) last year - TheFly
- 12 days ago - Biodesix Earnings Call Transcript: Q1 2026 - Transcripts
- 12 days ago - Biodesix raises FY26 revenue view to $108M-$114M from $106M-$112M - TheFly
- 12 days ago - Biodesix Announces First Quarter 2026 Results and Highlights - GlobeNewsWire
- 26 days ago - Eight option delistings on April 20th - TheFly
- 26 days ago - Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026 - GlobeNewsWire